Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.
Lucia Nogova
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Boehringer Ingelheim; Roche
Other Remuneration - Bayer; Lilly; Novartis; Pfizer
Lecia V. Sequist
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U); Taiho Pharmaceutical (U)
Research Funding - Novartis
Philippe Alexandre Cassier
Consultant or Advisory Role - SERVIER
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Novartis; Roche
Other Remuneration - Novartis; SERVIER
Manuel Hidalgo
No relevant relationships to disclose
Jean-Pierre Delord
Consultant or Advisory Role - Roche
Martin H. Schuler
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Wan-Teck Lim
Honoraria - Novartis
D. Ross Camidge
Consultant or Advisory Role - Novartis
Reinhard Buettner
Honoraria - Lilly; Merck; Novartis; Pfizer; Qiaga; Roche
Lukas Carl Heukamp
Consultant or Advisory Role - Qiagen
Honoraria - Novartis; Roche
Research Funding - Novartis
Masyar Gardizi
No relevant relationships to disclose
Matthias Scheffler
No relevant relationships to disclose
Kato Kambartel
No relevant relationships to disclose
Francois Philippe Ringeisen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Suman Sen
Employment or Leadership Position - Novartis
Randi Isaacs
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Maud Joannaert
Employment or Leadership Position - Novartis
Caroline Lefebvre
Employment or Leadership Position - Novartis
Juergen Wolf
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis